$215.10
▲ +2.4% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus
Quest Diagnostics Expands Oncology Testing Access Via Flatiron Health's OncoEMR MPI
Overview
52-week range
$165
$214
100% of range
Avg surprise (last 2)
+2.4%
Avg reaction (last 2)
+6.9%
100% positive
Latest IV / EM
40%
EM ±9.2% · $220 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $2.24 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $2.16 | — | — | — | — | financials |
| Tue Jul 22, 2025 | Jun/2025 | $2.62 | $2.57 | +1.9% | — | +7.1% | earnings |
| Tue Apr 22, 2025 | Mar/2025 | $2.21 | $2.15 | +2.8% | — | +6.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.99 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $2.03 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $1.72 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.96 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $2.05 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 23, 2026 | Jun/2026 | BMO | $2.81 | $2.62 | +7.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.90B | — | $2.82B | $2.76B | $2.65B | — | $2.49B | $2.40B |
| Cost of revenue | $1.95B | — | $1.87B | $1.82B | $1.79B | — | $1.68B | $1.59B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $399M | — | $386M | $438M | $346M | — | $330M | $355M |
| Net income | $252M | — | $245M | $282M | $220M | — | $226M | $229M |
| EPS (diluted) | $2.24 | — | $2.16 | $2.47 | $1.94 | — | $1.99 | $2.03 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M |
| Inventory | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M |
| Total current assets | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B |
| Total assets | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B |
| Long-term debt | — | — | — | — | — | — | $5.65B | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B |